Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

EP: 1.Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP: 2.Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

EP: 3.Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

EP: 4.RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

EP: 5.Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

Now Viewing

EP: 6.Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

EP: 7.Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

EP: 8.Emerging Therapies in RCC: Shaping Future Treatment Sequences

EP: 9.RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

Video content above is prompted by the following:

• In your experience, what patterns of progression are emerging with current frontline regimens for advanced RCC, and are there notable differences between IO/IO and IO/TKI combinations? How do these progression patterns—such as common sites of progression or timing—impact prognosis and influence your choice of subsequent therapy?
• When a patient progresses on frontline therapy, how do you approach treatment selection in the later-line setting?
• Does your choice differ based on whether the patient received IO-IO or IO-TKI in the first line? What clinical and disease-specific factors most influence your decision?